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Organ failure in the heart or kidney can initiate various
complex metabolic, cell-mediated and humoral path-
ways affecting distant organs, contributing to the high
therapeutic costs and significantly higher morbidity
and mortality. The universal outreach of cells in an in-
jured state has myriad consequences to distant organ
cells and their milieu. Heart performance and kidney
function are closely interconnected and communica-
tion between these organs occurs through a variety of
bidirectional pathways. The term cardiorenal syndrome
(CRS) is often used to describe this condition and rep-
resents an important model for exploring the patho-
physiology of cardiac and renal dysfunction. Clinical
evidence suggests that tissue injury in both acute kid-
ney injury and heart failure has immune-mediated in-
flammatory consequences that can initiate remote
organ dysfunction. Acute cardiorenal syndrome (CRS
type 1) and acute renocardiac syndrome (CRS type 3)
are particularly relevant in high-acuity medical units.
This review briefly summarizes relevant research and
focuses on the role of signaling in heart–kidney cross-
talk in the critical care setting.Clinical evidence suggests that tissue injury such asIntroduction
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© BioMed Central Ltd.2014acute and chronic cardiac disease can directly contribute
to concurrent acute/chronic worsening kidney function
and the converse [1,2]. The term cardiorenal syndrome
(CRS) is often used to describe this condition, represent-
ing an important model for exploring the pathophysi-
ology of cardiac and renal dysfunction [1,3]. The CRS
classification system includes a vast array of acute or
chronic conditions in these two important organs, where
the primary failing organ can be either the heart or the
kidneys. The current definition has been expanded into
five subtypes whose etymology reflects the primary and
secondary pathology, the time frame, as well as cardiac
and renal co-dysfunction secondary to systemic disease
[1] (Table 1). Epidemiological studies of CRS indicate
that patients transition between different CRS subtypes
[4]. There are a number of potential contributing factors
for CRS that may predispose a patient to the develop-
ment of this syndrome and which are relevant for the
susceptibility, etiology, severity and duration of the dis-
ease state. The intersection of cardiac and renal disor-
ders has important therapeutic and prognostic
implications; this new classification represents a step to-
wards a better understanding of the pathophysiology and
management strategies of this bidirectional crosstalk.
acute kidney injury (AKI) is not an isolated event and it
has become apparent that much of the increased risk of
death is derived from distant complications [5,6]. A re-
cent multicenter, multinational study reported that 5 to
6% of these at-risk patients suffer from AKI and subse-
quently are treated with renal replacement therapy
(RRT) [7]. Twenty-five percent of patients in the ICU
develop AKI [8,9]. RRT is the only US Food and Drug
Administration-approved treatment for AKI [10,11]. For
more than 40 years, despite the advent of RRT, there has
been limited improvement in the mortality rate associ-
ated with AKI [12]. In the critical care setting, AKI re-
mains an important predictor of outcome, and
frequently results in remote organ dysfunction involving
the heart, lung, liver, intestines, and brain through




CRS type 1 Abrupt worsening of cardiac function leading to acute kidney injury; for example, acute coronary syndrome
causing acute heart failure and then renal dysfunction
Chronic cardiorenal
syndrome




CRS type 3 Sudden worsening of renal function causing acute cardiac dysfunction; for example, uremic
cardiomyopathy secondary to acute renal failure
Chronic renocardiac
syndrome
CRS type 4 Condition of primary chronic kidney disease leading to an impairment of the cardiac function and/or
increased risk of adverse cardiovascular events; for example, left ventricular hypertrophy and diastolic heart
failure secondary to renal failure
Secondary cardiorenal
syndrome
CRS type 5 Systemic disorders causing both cardiac and renal dysfunction; for example, septic shock, vasculitis
CRS, cardiorenal syndrome.
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the organ crosstalk, the combination of AKI with acute
lung injury remains a formidable challenge for clinicians
treating critically ill patients. New experimental data
have emerged in recent years focusing on the interactive
effects of kidney and lung dysfunction, and providing
evidence that kidney–lung crosstalk occurs and can
be bidirectionally deleterious. These studies have
highlighted the pathophysiological importance of proin-
flammatory and proapoptotic pathways in the kidney–
lung crosstalk [16,17]. Inflammatory dysregulation
resulting from each organ failure results in rising levels
of circulating chemokines, cytokines and activated lym-
phocytes [17]. Cellular (for example, neutrophils) as well
as soluble mediators (cytokines) contribute to the in-
flammatory dysregulation under these circumstances
[18].
The liver and kidney are important regulators of
body homeostasis and are involved in excreting the
toxic byproducts of metabolism and exogenous drugs
[19]. Liver injury often correlates with severity of kid-
ney injury. AKI induces oxidative stress and promotes
inflammation (production of TNFα, IL-1, IL-6), apop-
tosis and tissue damage in hepatocytes [20-23]. An-
other important mechanism of end-organ dysfunction
in kidney–liver crosstalk is the development of hepa-
torenal syndrome, a functional renal failure that often
occurs in patients with cirrhosis and ascites. Two dif-
ferent types of hepatorenal syndrome have been de-
scribed. Hepatorenal syndrome type 1 develops as a
consequence of a severe reduction of effective circu-
lating volume due to both an extreme splanchnic ar-
terial vasodilatation and a reduction of cardiac
output. Hepatorenal syndrome type 2 is characterized
by a stable or slowly progressive renal failure, so that
its main clinical consequence is not acute renal fail-
ure but refractory astrocytes, and its impact on prog-
nosis is less negative [24,25]. Effects of AKI on the
brain and the nervous system include several clinical
signs [26]. In addition, cerebral inflammation andfunctional changes were demonstrated after AKI
[27,28]. AKI also led to increased levels of proinflam-
matory chemokines, keratinocyte-derived chemo-
attractant, and granulocyte colony-stimulating factor
in the cerebral cortex and hippocampus, which may
function to recruit neutrophils to sites of neuronal
damage, and to increased expression of glial fibrillary
acidic protein in astrocytes in the cortex and corpus
callosum [23]. AKI also induces a cell-mediated in-
flammatory response in the brain by activation of
microglial cells (brain macrophages) [23].
In cardiorenal crosstalk, acute cardiorenal syndrome
(CRS type 1) and acute renocardiac syndrome (CRS type
3) are particularly relevant in high-acuity medical units;
in particular, CRS type 1 is often seen in the coronary
care unit and in the ICU (Figure 1). The purpose of this
review is to examine the burden of concomitant heart
and renal dysfunction in critically ill patients. Recent
work on AKI has shown that inflammatory cascades, cell
adhesion molecule, cytokine and chemokine upregulated
expression, neutrophil migration, leukocyte trafficking,
caspase-mediated apoptosis, and oxidative stress puta-
tively induce distant organ dysfunction [27]. During
AKI, chemokines recruit neutrophil infiltration into the
heart and cause myocyte apoptosis [29,30]. Additional
complications include oxidative loss of redox homeosta-
sis in reactive oxygen species (ROS) and reactive nitro-
gen species, resulting in a proinflammatory and
profibrotic milieu via distinct mechanisms that promote
cardiovascular and renal structural and functional abnor-
malities, including ischemia/reperfusion injury (IRI)
[31,32]. The physiological crosstalk is necessary to main-
tain regular homeostasis and normal functioning of the
organism. However, in the diseased state, the immediate
and concomitant induction of toxic cell signaling by the
primary damaged organ can induce structural and func-
tional dysfunction in distant organs [33].
The evaluation of known mechanisms and putative
targets underlying the pathophysiology of heart–kidney
crosstalk encompasses innate and adaptive immunity,
Figure 1 Cardiorenal syndrome type 1 and cardiorenal syndrome type 3. (a) Cardiorenal syndrome (CRS) type 1 is characterized by acute
worsening of heart function leading to acute kidney injury (AKI) and/or dysfunction. Acute cardiac events that may contribute to AKI include
acute decompensated heart failure, acute coronary syndrome, cardiogenic shock and cardiac surgery-associated low cardiac output syndrome. (b)
CRS type 3 is characterized by acute worsening of kidney function leading to acute cardiac injury and/or dysfunction, such as acute myocardial in-
farction, congestive heart failure, or arrhythmia. Conditions that may contribute to this syndrome include cardiac surgery-associated AKI, AKI after
major noncardiac surgery, contrast-induced AKI, other drug-induced nephropathies, and rhabdomyolysis. ACE, angiotensin-converting enzyme;
GFR, glomerular filtration rate; RAA, rennin-angiotensin-aldosterone.
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apoptosis, renal tubular epithelium and renal vascular
endothelium alterations.
Renal tubular epithelium and renal vascular
endothelium
The proximal tubular epithelial cells reabsorb numerous
substances from the 140 liters of plasma ultrafiltrate that
the normal kidney produces each day, substances that
include small peptides and immune regulatory molecules
as well as electrolytes and nitrogenous waste products
[34]. Proximal tubular cells also actively secrete mole-
cules from the peritubular capillary bed into the tubular
lumen. Finally, proximal tubular cells are immunologic-
ally active, presenting antigen and producing a variety of
inflammatory mediators [35-39].
The CD40/CD40-ligand (CD40L) pathway is a key me-
diator of cellular responses to injury and the resulting
vascular pathophysiology. CD40 is a cell surface glyco-
protein that belongs to the TNF-receptor superfamily,
largely expressed on the cellular surface of antigen-
presenting cells, including B lymphocytes, macrophages,
and dendritic cells. CD40 is also present in some non-
lymphoid cells, such as tubular epithelial cells, where it
has been suggested to play a role in the pathogenesis of
renal inflammatory response [40,41]. Stimulation in re-
sponse to injury of CD40 receptor–CD40L has pleio-
tropic effects both on immune and nonimmune cells
including downstream cellular and humoral immuneresponse, microglial activation, and TNFα production.
CD40/CD40L interaction induces in vitro the production
of different proinflammatory cytokines, including IL-8,
monocyte chemoattractant protein-1, and RANTES, by
proximal tubular epithelial cells and modulates the re-
sponse to inflammatory stimuli [40,42]. These different
cytokines, chemokines, and adhesion molecules serve as
chemoattractants for additional leukocytic infiltrates, in-
cluding monocytes and T lymphocytes [43,44]. In par-
ticular, Laxmanan and colleagues found that human
renal proximal tubular epithelial cells treated with sol-
uble CD40L to ligate CD40 showed a significant increase
in the generation of proinflammatory ROS; however,
CD40-activated cells did not undergo apoptosis [45].
Recently, some studies focused on the contribution of
tubular epithelial cells to the typical systemic inflamma-
tory response of CRS and other pathologic conditions
[29,46]. Complex signaling systems including crosstalks,
feedback and feedforward loops polarize the cellular mi-
lieu in the pathophysiological profile, and include the ex-
pression of co-stimulatory pathways. An inexorable
assemblage of evidence indicates that the clinical pat-
terns in heart and kidney dysfunction are a direct result
of cellular and subcellular remodeling processes [47-52].
Furthermore, renal tubular cells play a critical role in the
handling of inflammatory mediators and in their result-
ing efflux into systemic circulation [50,53]. These cells
contribute to the circulating levels of inflammatory me-
diators by different mechanisms, including epigenetic
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valent modifications of DNA and associated proteins, al-
terations in chromatin structure, and recruitment of a
diversity of signal responsive transcription factors and
enzymes [54,55]. In particular, Zager and Johnson dem-
onstrated the upregulation of histone-modifying enzyme
systems and the alteration of histone expression at pro-
inflammatory and profibrotic genes such as TNFα and
monocyte chemoattractant protein-1 in IRI [56-58].
Allam and colleagues recently identified extracellular
histones as mediators of postischemic and septic AKI.
Histones are released from dying tubular epithelial cells
and act as damage-associated molecular patterns, which
require toll-like receptor (TLR)2 and TLR4 for the in-
duction of proinflammatory cytokines; extracellular his-
tones aggravate AKI via both its direct toxicity to renal
endothelial cells and tubular epithelial cells and its pro-
inflammatory effects [59].
Epigenetic changes, cellular signaling and humoral
pathways create the cellular milieu and pathophysio-
logical profile, depending on the timing, disease setting,
and stimulation state. These biological events may play a
role in heart–kidney crosstalk and in the increase of sys-
temic inflammation and distant organ injury.
Renal vascular endothelial cells initiate early inflamma-
tory responses in the injured kidney by direct contact
with injurious agents [60]. The injured kidney is known
to modulate the activity of leukocytes [61-63]. The ische-
mic injury damages the barrier function of endothelium,
resulting in disorganization of endothelial integrity pro-
ducing partial disappearance of cell–cell borders and
disruption of cell–cell contacts [46]. Endothelial disinte-
gration thus increases vascular permeability and facili-
tates leukocyte infiltration into the renal parenchyma.
Recent studies have investigated the leukocyte–endothe-
lium interactions. Down regulation of Netrin-1, a protein
involved in development of the nervous system and epi-
thelial tissues, in renal vascular endothelial cells in peri-
tubular capillaries may promote endothelial cell
activation, resulting in extravasation of leukocytes into
the kidney and tubular injury [64,65]. Furthermore,
sphingosine-1-phosphate maintains endothelial cell in-
tegrity and inhibits lymphocyte extravasations via the
sphingosine-1-phospate receptor. A recent study showed
that a sphingosine-1-phosphate selective agonist amelio-
rates ischemic acute renal failure [66]. In addition to
changes in the integrity of the renal vascular endothe-
lium layer, IRI upregulates the expression of adhesion
molecules, in particular intracellular adhesion molecule-
1, that promote and facilitate the interactions between
leukocytes and the endothelium [29,67]. Leukocyte adhe-
sion causes inflammation and extension of cellular in-
jury. Renal tubular epithelium is a major site of cell
injury and cell death during AKI and numerous studieshave suggested that renal epithelial cells have a central
role in inflammation during AKI. This effect could
modulate cell behavior in distant organs, such as the
heart and lung, with potentially deleterious effects and
creating a vicious circle.
Immunomodulation: the role of innate and
adaptive immunity
Recent studies have highlighted the importance of both
innate and adaptive immune responses to endogenous
molecules induced by either tissue damage or infection
[68,69]. The innate immune system is immediately acti-
vated in infection states and inflammatory conditions in
a nonantigenic-specific way. This activation is executed
primarily by myeloid cells with the participation of some
innate lymphocyte subpopulations and is comprised of
neutrophils, monocytes/macrophages, dendritic cells
(DCs), natural killer cells and natural killer T cells
(Figure 2). Leukocytes such as DCs and macrophages
play important functions in both types of immunity by
generating cytokines, chemokines and presenting anti-
gens to lymphocytes [29,68]. Adaptative immunity is a
second line of defense responding to specific antigens in
cellular and humoral response pathways. T-cell
polarization in response to DC activation is complex
and involves myriads of signaling cascades. Critical sig-
naling cascades from both intrinsic and extrinsic factors
come down to a single bridge. Activation of both innate
and adaptive immune responses is regulated by the TLR
pathways. Briefly, DC maturation and antigen presenta-
tion, CD4 and CD8 lymphocyte proliferation and stimu-
lation, and consequently T-lymphocyte to B-lymphocyte
interactions lead to specific morphological and cell sig-
naling upregulation. Specific subpopulations of T cells
have been implicated in deleterious cell fate pathways,
contributing to organ damage [70]. Proposed initiators
of the innate immune response during AKI include the
activation of TLRs and the release of ROS, reactive ni-
trogen species and mitochondrial products [71]. TLRs
are the major pattern recognition receptors, binding to a
wide range of different molecules and, in particular, en-
dogenous ligands produced as a consequence of tissue
injury. This pathogenesis, specifically TLR signaling,
causes a rapid response mechanism to local tissue dam-
age and is involved in early activation of the immune re-
sponse in AKI events [15].
The adaptive immune system is stimulated by the spe-
cificity of antigen receptors on B and T lymphocytes that
react to several antigenic molecular structures. Once
stimulated, B cells produce specific antibodies, perform
opsonization to encourage phagocytosis, and activate the
complement system [15]. Antigen-dependent T-cell acti-
vation has been demonstrated in experimental models of
renal IRI [61,72]. Inflammation of renal tissue stimulates
Figure 2 Cellular types involved in heart–kidney crosstalk.
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cells, which leads to the deposition of immune com-
plexes and vascular stiffening in kidney disease
[15,73,74]. Either following antigen activation or in the
presence of chemokines and ROS/reactive nitrogen spe-
cies, T cells undergo early activation and function as a
bridge between adaptive and innate immune systems.
This specific immune response in AKI facilitates and en-
hances distant heart–kidney crosstalk.
AKI is involved in the functional abnormalities in im-
mune cell responsiveness and alterations such as
leukocyte trafficking, adhesion and tissue extravasation
both locally in the kidney and in distal organs such as
the heart in CRS type 3. In ischemia animal models,
morphological and functional changes in vascular endo-
thelial cells and in tubular epithelium have been exten-
sively confirmed [29,46,75,76]. Leukocyte activation and
trafficking play a critical role in heart injury during AKI.
Neutrophils, macrophages, natural killers and lympho-
cytes infiltrate into the injured kidneys. The injury
prompts the activation of inflammatory pathways by
tubular and endothelial cells recruiting leukocytes intothe kidneys [29,46]. In particular, in IRI models, after ad-
herence and chemotaxis, neutrophils release ROS, prote-
ases, and myeloperoxidase, and other cardiorenal
mediators directly damage the tissue with local and sys-
temic effects including upregulation of proinflammatory
cytokines and chemokines, both critical players in heart
failure (HF) [77,78]. During AKI, chemokines recruit in-
flammatory cells with a consecutive neutrophil infiltra-
tion into the heart tissue and this is a causal factor of
myocyte apoptosis [29,30], typical of CRS type 3.
The dominant resident leukocyte types present in the
kidney are resident intrarenal DCs, suggesting a crucial
role in renal immunity and inflammation. In fact, in the
normal mouse CD11c+ major histocompatibility com-
plex class II+ DCs are the most abundant leukocyte sub-
set in the kidney, suggesting an important role in renal
immunity and inflammation [29]. Furthermore, intrare-
nal DCs are an important link between innate and adap-
tive immunity; unfortunately, the individual contribution
of intrarenal DCs to the pathophysiology of AKI is not
completely understood. These cells are located in the
interstitial extracellular compartment of the whole
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many different factors [79-81]. Within this compart-
ment, DCs are close to epithelial cells, macrophages,
and fibroblasts, and they respond to endogenous mole-
cules released from resident and/or infiltrating cells
[80-82]. DCs are a heterogeneous population with differ-
ent functions. Upon stimulation, DCs can convert to a
mature cell type characterized by high levels of class II
major histocompatibility complex and co-stimulatory
molecules and low phagocytic capacity. Mature DCs are
specialized in T-cell activation. However, DCs are also
important in the innate immune response by releasing
proinflammatory factors, such as TNF, IL-6, IL-12,
monocyte chemoattractant protein-1 and RANTES, and
interacting with natural killer T cells via CD40–CD40L
[29,83]. Recent studies have shown that DCs can im-
prove or prevent injury to the kidney depending on the
nature of stimulus. For example, depletion of DCs prior
to IRI reduces consequent reperfusion injury and related
renal dysfunction [84]. Conversely, depletion of DCs
prior to cisplatin exposure resulted in worse renal dys-
function and stronger inflammation [85]. DCs have a
central role in orchestrating the immune response in
AKI; additional studies are needed to understand the de-
tailed functions of these cells in the CRS and in the
heart–kidney crosstalk.
Role of inflammation, cytokines and chemokines
The unbalancing of the cytokine and chemokine net-
works in inflammation accelerates the deposition of ath-
erosclerotic plaques, mediates insulin resistance,
stimulates tumor growth and causes increases in adhe-
sion molecule expression and vascular permeability.
Nonresolving and persistent exposure to proinflamma-
tory factors, such as TNFα, IL-1, IL-4, IL-6, IL-13, and
IL-17, damages tissue, impairs organ function and is le-
thal in the critical care setting. The cytokines, chemo-
kines, and eicosanoids mediate cellular responses and
interact with genome-encoded receptors expressed on
monocytes, macrophages, mast cells, astrocytes, and
other cells of the innate immune system [86]. Upregula-
tion of humoral factors by injured cells leads to activa-
tion of the toll/IL-1 superfamily. Members of this
superfamily signal in a similar manner using a conserved
domain that actives nuclear factor-κB, which translo-
cates the nucleus resulting in changes in gene expres-
sion. TLR pathways, activated via nuclear factor-κB,
result in both intracellular and extracellular upregulaton
of inflammatory cytokine expression [87,88].
Over the past 30 years there has been growing evi-
dence for the role played by activation of the inflamma-
tory response in the pathogenesis of acute events of HF
at various levels in these patients [89,90]. Further sup-
port for the inflammatory etiology of HF came from theevidence that cytokines may also be produced by cardio-
myocytes, following ischemic or mechanical stimuli, but
also by innate immune response [91-93]. These findings
suggest that an immune dysregulation may occur in HF;
cytokines not only could provoke distant organ damage
such as AKI and CRS type 1, but they may also play a
role in concomitant damaging myocytes. In the Program
to Improve Care in Acute Renal Disease, a prospective
multicenter cohort study, TNFα, IL-1β, IL-6, IL-8 and
C-reactive protein were increased in critically ill patients
with acute renal failure [94]. These results provide evi-
dence that an inflammatory systemic response is stimu-
lated and maintained in critically ill patients with AKI
that probably contributes to distant organ dysfunction,
and in particular cardiac dysfunction.
Studies of CRS type 3 have expanded the understand-
ing of heart–kidney crosstalk by demonstrating induc-
tion of cardiac damage by inflammatory mediators,
oxidative stress and upregulation of neuroendocrine sys-
tems early following AKI [13,30,95].
In IRI animal models, AKI has been highlighted to
elicit a systemic immune response characterized by a
dose–response increase in circulating proinflammatory
and anti-inflammatory factors. Likewise, AKI may be as-
sociated with physiologic derangements, alterations to
coronary vasoreactivity, ventricular remodeling and fi-
brosis that indirectly strengthens negative effects on car-
diomyocytes and causes cardiac dysfunction [96-98].
Several inflammatory mediators, such as TNFα, IL-1β
and IL-6, have been implicated in cardiodepressant ef-
fects, and cytokines can impact myocardial function due
to both impaired myocyte contractility and extracellular
matrix interaction [95,98,99]. In general, cytokine-
mediated contractile dysfunction is reversible over an
extended time period of several days following exposure
[95].
Apoptosis
TLR activation of cell-mediated, humoral, and inflam-
matory responses can lead to changes in cell fate, or in
the worst case to continued heightened activation apop-
totic induction. TLR induction of caspase-mediated
apoptosis is a key pathogenic feature in kidney disease
whereby renal tubular epithelial cells cease to proliferate
and embark upon terminal differentiation. Apoptosis is a
controlled and physiological mechanism of regulation of
cell populations in an endogenously programmed pat-
tern, and it plays a very important role especially in the
immune system, during development of lymphocytes as
in antigen recognition [100]. A loss of immune cells by
apoptosis is associated with physiologic changes that
occur in several diseases, and the host response requires
a fine equilibrium between recruitment and death of im-
munocompetent cells [100].
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apoptosis in AKI and in the development of HF [101].
Two main intracellular pathways for apoptosis have been
recognized: ligation of plasma membrane death recep-
tors (extrinsic pathway), and perturbation of the intra-
cellular homeostasis (intrinsic pathway). The two
pathways are linked, and molecules in one pathway can
influence the other [102]. In the extrinsic pathway, the
Fas/Fas-ligand system transmits apoptotic signals from
the surrounding environment into the cell; the binding
of Fas ligand with Fas initiates receptor oligomerization,
which recruits Fas-associated death domain and the acti-
vators caspase-8 and caspase-10 [103-105]. These cas-
pases are activated upon oligomerization and then cleave
protein substrates to activate downstream effector cas-
pases. The intrinsic pathway involves intracellular organ-
elles, the most important being mitochondria [106-108].
The permeabilization of the outer mitochondrial mem-
brane and the release of proapoptotic factors such as
cytochrome c promote caspase-dependent and caspase-
independent apoptosis [106]. Caspases are widely
expressed in an inactive proenzyme form in most cells
and once activated can often activate other pro-caspases,
allowing initiation of a protease cascade. This proteolytic
cascade, in which one caspase can activate other cas-
pases, amplifies the apoptotic signaling pathway and
thus leads to rapid cell death [109,110]. Over the last
few years, many studies have demonstrated that survival
factors and anti-cytokine strategies can prevent apop-
tosis in vivo [111-114]; better characterization of the
molecular pathways activated at each stage of apoptosis
and an understanding of the time frames will be crucial
to developing new sensible therapeutic strategies.
The multiple factors involved in the development of
AKI during HF describe a pathogenesis of AKI account-
ing for multiple pathways. Evidence suggests that an
immune-mediated mechanism has been implicated in
CRS type 1 pathogenesis [115,116]. CRS type 1 plasma-
induced apoptosis with caspase cascade and IL-6 were
recently shown to be significantly higher in CRS type 1
patients when compared with healthy subjects and with
HF patients without kidney impairment [115,116]. Lim-
ited data are available about cardiac-specific cellular re-
sponses associated with AKI, including the role of
mitochondrial dysfunction, apoptosis, cardiac remodel-
ing and fibrosis. Some experimental models have ex-
plained the role of apoptosis in AKI setting. Prolonged
ischemia followed by reperfusion triggers apoptosis and
inflammation, leading to tissue damage and organ dys-
function [117-119]. Cardiac myocyte apoptosis and neu-
trophil infiltration/activation are key contributors to the
pathophysiology of myocardiac infarction during AKI,
and transgenic rat models have shown that even apop-
tosis can lead to tissue damage and lethal heartdysfunction [30]. In particular, Kelly demonstrated that
kidney IRI but not uremia is fundamental to trigger
apoptosis in myocardial tissue [30]. Another experimen-
tal rat model of cisplatin-induced AKI showed signifi-
cant increased levels of myocardial apoptosis by terminal
deoxynucleotidyl transferase dUTP nick end-labeling
assay [120]. Proinflammatory cytokine TNFα contributes
directly to in vitro cardiomyocyte apoptosis depression
of contractility, and to downregulation of sarcomeric
proteins [121-123]. Furthermore, attenuation of apop-
tosis following administration of anti-TNFα antibodies
was demonstrated and clearance of TNFα as a novel
therapeutic strategy was hoped to improve HF [30].
Cardiorenal syndrome type 5
A brief part of this review is focused on CRS type 5, in
which the heart and the kidney are both targets of a
strong systemic inflammatory reaction [124]. CRS type 5
reflects concomitant cardiac and renal dysfunction in
the setting of a wide spectrum of systemic disorders,
such as diabetes mellitus, systemic lupus erythematosus
and sepsis [1,125,126]. In CRS type 5, cardiac dysfunc-
tion and renal dysfunction are often observed and are
part of the clinical picture of severe sepsis, septic shock
and multiple organ failure [1,127]. Following the RIFLE
criteria, AKI ranges from minor alterations in renal
function to indication for RRT in critically ill patients
[128]. AKI is a common complication in septic patients
and carries a poor prognosis. AKI occurs in 20% of crit-
ically ill patients, and in 51% of patients with septic
shock and positive blood cultures [129]. Cardiac dys-
function in sepsis is characterized by decreased contract-
ility, impaired ventricular response to fluid therapy,
progressive ventricular dilatation and myocardial depres-
sion [124,127]. CRS type 5 is characterized by general-
ized inflammatory response and by activation of
coagulation and the fibrinolytic system, and induces cel-
lular and molecular changes in the heart and kidneys
[125,126,130]. This inflammatory reaction is particularly
relevant for sepsis in which the majority of mechanisms
of immune-mediated heart and kidney tissue injury have
been described in detail [131-134]. In particular, several
studies have shown in critically ill patients that inflam-
matory mediators, release of nitric oxide and increased
production of peroxynitrite are able to alter organ func-
tion and cause abnormal cell signaling, cell cycle arrest,
and mitochondria dysfunction, and can induce direct
proapoptotic and proinflammatory effects on cardiomyo-
cytes and kidney resident cells such as podocytes, endo-
thelial cells, mesangial cells and particularly tubular
epithelial cells [3,124,135-140]. Recently, apoptosis was
put forward as a major player in septic AKI [141]. Ler-
olle and colleagues studied kidney biopsies from 19 pa-
tients who died from septic shock and compared them
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tients and from nine patients with nonseptic AKI. Acute
tubular apoptosis was demonstrated by different tech-
niques in septic AKI whereas almost no apoptosis was
detected in the nonseptic AKI patients [141]. Indeed, in-
flammatory mediators, activation and induction of cyto-
kines, leukocytes and toll receptors play a key role in the
pathogenesis of renal and cardiac dysfunction during
sepsis [125,142]. Inflammatory cytokines such as TNFα
and IL-6 trigger apoptosis in tubular epithelial cells,
probably playing a role in tissue damage, and TNFα and
IL-1 are the principal culprits in the pathogenesis of car-
diac dysfunction during sepsis [137,143-146].
Conclusions
Immune response orchestrates healing and tissue gener-
ation, and eradication of pathogens, yet the danger of
uncontrolled inflammation is a core homeostatic
phenomenon in human disease and distant organ dam-
age. Dysregulation of crosstalk between the heart and
kidney is probably a therapeutic option, which currently
includes cytokines, chemokines, and growth factors
known to initiate intercellular and intracellular changes.
Signaling pathways from damaged cells in either the
heart or the kidney promote innate immune activation
and strengthen adaptive immunity. Other targets may
include serine/threonine kinases such as Akt capable of
apoptotic cycle inhibition and repairing stimulation
pathways in response to damage resulting from extracel-
lular stimuli to control regulation of nutrient metabol-
ism and survival [147]. Rapid characterization of cellular
and subcellular research in human and animal models
continues to elucidate the complex crosstalk as well as
putative epigenetic changes resulting from brief or
chronic states of immune–inflammatory changes in gene
expression.
Heart–kidney crosstalk has significant clinical rele-
vance, and the current review highlights the humoral
mechanism involved in multiorgan failure. In particular,
the management of acute CRS subtypes is challenging
because of the multitude and complexity of pathophysio-
logical interactions between the heart and the kidney
and the possible progression from acute to chronic in-
jury in these organs. In critical illness, the complete
characterization of cellular and subcellular orchestration
in heart–kidney crosstalk and the early recognition of
disease by new biomarkers could allow choice of the best
therapeutic options, prevention of the necessity for RRT,
shorten the AKI duration, limit multiple organ injury
and improve survival. The combination of clinical status
and new functional and damage biomarkers provides a
novel set of tools for the clinician to manage patients
with CRS. Present and future studies on pathogenetic
mechanisms involved in cardiorenal crosstalk will allowthe development not only of better directed but also
more appropriately timed therapeutic strategies to im-
prove outcome in these patients.
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